JP2003525061A - 高効力組換え抗体およびその産生法 - Google Patents
高効力組換え抗体およびその産生法Info
- Publication number
- JP2003525061A JP2003525061A JP2001564244A JP2001564244A JP2003525061A JP 2003525061 A JP2003525061 A JP 2003525061A JP 2001564244 A JP2001564244 A JP 2001564244A JP 2001564244 A JP2001564244 A JP 2001564244A JP 2003525061 A JP2003525061 A JP 2003525061A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- potency
- amino acid
- high potency
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 143
- 230000008569 process Effects 0.000 claims abstract description 56
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 54
- 239000000427 antigen Substances 0.000 claims abstract description 46
- 108091007433 antigens Proteins 0.000 claims abstract description 45
- 102000036639 antigens Human genes 0.000 claims abstract description 45
- 239000012634 fragment Substances 0.000 claims abstract description 38
- 238000009739 binding Methods 0.000 claims abstract description 35
- 230000027455 binding Effects 0.000 claims abstract description 34
- 241000700605 Viruses Species 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 244000005700 microbiome Species 0.000 claims abstract description 12
- 230000000890 antigenic effect Effects 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 3
- 201000011510 cancer Diseases 0.000 claims abstract description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 163
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 59
- 150000001413 amino acids Chemical class 0.000 claims description 51
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 37
- 238000006243 chemical reaction Methods 0.000 claims description 34
- 238000012216 screening Methods 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 5
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000003440 toxic substance Substances 0.000 claims description 3
- 231100000167 toxic agent Toxicity 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 230000001965 increasing effect Effects 0.000 abstract description 24
- 231100000765 toxin Toxicity 0.000 abstract description 5
- 239000003053 toxin Substances 0.000 abstract description 5
- 108700012359 toxins Proteins 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 33
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 20
- 229920001184 polypeptide Polymers 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 238000006467 substitution reaction Methods 0.000 description 17
- 238000010494 dissociation reaction Methods 0.000 description 15
- 230000005593 dissociations Effects 0.000 description 14
- 230000004071 biological effect Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 11
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 11
- 238000003556 assay Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000009918 complex formation Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000144290 Sigmodon hispidus Species 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000004896 polypeptide structure Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002515 oligonucleotide synthesis Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000000111 isothermal titration calorimetry Methods 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000867614 Mimus polyglottos Species 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000144282 Sigmodon Species 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- KUHRIIPUCPOQMQ-UHFFFAOYSA-N n,n-diethyl-3-(ethyliminomethylideneamino)propan-1-amine Chemical compound CCN=C=NCCCN(CC)CC KUHRIIPUCPOQMQ-UHFFFAOYSA-N 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 101150085502 panF gene Proteins 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18625200P | 2000-03-01 | 2000-03-01 | |
| US60/186,252 | 2000-03-01 | ||
| PCT/US2001/006815 WO2001064751A2 (en) | 2000-03-01 | 2001-03-01 | High potency recombinant antibodies and method for producing them |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010026290A Division JP2010162025A (ja) | 2000-03-01 | 2010-02-09 | 高効力組換え抗体およびその産生法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003525061A true JP2003525061A (ja) | 2003-08-26 |
| JP2003525061A5 JP2003525061A5 (US07700735-20100420-C00027.png) | 2010-04-30 |
Family
ID=22684221
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001564244A Pending JP2003525061A (ja) | 2000-03-01 | 2001-03-01 | 高効力組換え抗体およびその産生法 |
| JP2010026290A Pending JP2010162025A (ja) | 2000-03-01 | 2010-02-09 | 高効力組換え抗体およびその産生法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010026290A Pending JP2010162025A (ja) | 2000-03-01 | 2010-02-09 | 高効力組換え抗体およびその産生法 |
Country Status (10)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| ATE474854T1 (de) * | 2000-01-27 | 2010-08-15 | Medimmune Llc | Rsv neutralisierende antikörper mit sehr hohen affinität |
| EP2341075A1 (en) * | 2000-03-01 | 2011-07-06 | MedImmune, LLC | Antibodies binding to the f protein of a respiratory syncytial virus (rsv) |
| EP2412384A1 (en) * | 2000-11-28 | 2012-02-01 | MedImmune, LLC | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US6855493B2 (en) * | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| ES2727425T3 (es) | 2000-12-12 | 2019-10-16 | Medimmune Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| WO2003063767A2 (en) * | 2001-11-02 | 2003-08-07 | Centocor | Rsv proteins, antibodies, compositions, methods and uses |
| EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
| ATE509032T1 (de) * | 2002-02-13 | 2011-05-15 | Ludwig Inst For Cancer Res Ltd | Chimerizierte gm-csf antikörper |
| US20040028685A1 (en) * | 2002-05-10 | 2004-02-12 | Kinch Michael S. | EphA2 monoclonal antibodies and methods of use thereof |
| US20050152899A1 (en) * | 2002-05-10 | 2005-07-14 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
| AU2003276832A1 (en) * | 2002-05-10 | 2004-02-25 | Medimmune, Llc | EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| JP2005533861A (ja) * | 2002-07-25 | 2005-11-10 | メデュームン，インコーポレーテッド | 抗ＲＳＶ、抗ｈＭＰＶ、および抗ＰＩＶ抗体を使用するＲＳＶ、ｈＭＰＶ、およびＰＩＶの治療法と予防法 |
| AU2004207741B2 (en) | 2003-01-24 | 2011-02-10 | Applied Molecular Evolution, Inc | Human IL-1 beta antagonists |
| WO2004092343A2 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
| US20050059592A1 (en) * | 2003-04-11 | 2005-03-17 | Kiener Peter A. | EphA2 and hyperproliferative cell disorders |
| US7070786B2 (en) | 2003-06-06 | 2006-07-04 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
| EP1720908A2 (en) * | 2004-02-17 | 2006-11-15 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
| EP1853630A1 (en) * | 2004-10-22 | 2007-11-14 | Applied Molecular Evolution Inc. | Methods of optimizing antibody variable region binding affinity |
| EP1812068A4 (en) * | 2004-10-29 | 2010-06-09 | Medimmune Inc | METHODS FOR PREVENTING AND TREATING RSV INFECTIONS AND ASSOCIATED DISEASES |
| BRPI0708636A2 (pt) * | 2006-03-06 | 2011-06-07 | Symphogen As | anticorpo policlonal recombinante para tratamento de infecções por vìrus sinciciais respiratórios |
| WO2008070042A2 (en) * | 2006-12-04 | 2008-06-12 | Medimmune, Inc. | High potency recombinant antibodies, methods for producing them and use in cancer therapy |
| CN101679513A (zh) * | 2007-03-06 | 2010-03-24 | 西福根有限公司 | 用于治疗呼吸道合胞病毒感染的重组抗体 |
| EP1997830A1 (en) * | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| JP2010531878A (ja) | 2007-06-27 | 2010-09-30 | マリン ポリマー テクノロジーズ，インコーポレーテッド | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| US8187601B2 (en) * | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| US8775090B2 (en) | 2008-12-12 | 2014-07-08 | Medimmune, Llc | Crystals and structure of a human IgG Fc variant with enhanced FcRn binding |
| WO2010085590A1 (en) | 2009-01-23 | 2010-07-29 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria |
| WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| EP2464661B1 (en) | 2009-08-13 | 2018-01-17 | The Johns Hopkins University | Methods of modulating immune function with anti-b7-h7cr antibodies |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| WO2011062560A1 (en) * | 2009-11-19 | 2011-05-26 | National University Of Singapore | Method for producing t cell receptor-like monoclonal antibodies and uses thereof |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| SI2704743T1 (sl) * | 2011-05-04 | 2020-08-31 | Omeros Corporation | Sestave za zaviranje sprožitve komplementov, odvisnih od masp-2 |
| CN107602700B (zh) | 2011-05-20 | 2021-12-17 | H.伦德贝克公司 | 抗cgrp组合物及其用途 |
| CA2836800A1 (en) | 2011-05-20 | 2012-11-29 | Alderbio Holdings Llc | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| US9855332B2 (en) | 2011-05-20 | 2018-01-02 | Alderbio Holdings Llc | Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels |
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| EP4011919A3 (en) * | 2015-12-09 | 2022-10-12 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
| KR20190103147A (ko) | 2016-10-21 | 2019-09-04 | 아디맵 엘엘씨 | 항-호흡기 세포융합 바이러스 항체, 그리고 이의 생성 방법 및 사용 방법 |
| AU2017345786A1 (en) | 2016-10-21 | 2019-05-23 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| JP7265984B2 (ja) | 2016-10-21 | 2023-04-27 | アディマブ， エルエルシー | 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 |
| MX2021008267A (es) | 2019-01-08 | 2021-08-05 | H Lundbeck As | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp. |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06506836A (ja) * | 1991-04-10 | 1994-08-04 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二重体受容体ライブラリー |
| JPH10504195A (ja) * | 1994-08-15 | 1998-04-28 | メディミューン，インコーポレイテッド | 呼吸シンシチアルウイルスを防ぐヒト−マウスキメラ抗体 |
| JP2001511149A (ja) * | 1997-01-30 | 2001-08-07 | イクシーズ，インコーポレイテッド | 抗αｖβ３組換えヒト化抗体、これをコードする核酸、および使用の方法 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA814386B (en) | 1980-07-01 | 1982-07-28 | Nat Res Dev | Production of viral antigens |
| JPS58500366A (ja) | 1981-03-06 | 1983-03-10 | セルテツク リミテツド | 単一クロ−ン抗体 |
| DE3378250D1 (en) * | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
| US5340926A (en) | 1983-03-25 | 1994-08-23 | Celltech, Limited | Process for the recovery of recombinantly produced protein from insoluble aggregate |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US5332805A (en) | 1984-02-03 | 1994-07-26 | Celltech Limited | Process for the recovery of recombinantly produced chymosin from insoluble aggregate |
| US5128326A (en) * | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| FR2590674B1 (fr) | 1985-11-25 | 1989-03-03 | Inst Nat Sante Rech Med | Nouveaux reactifs de diagnostic |
| US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
| US4717766A (en) | 1986-01-27 | 1988-01-05 | Miles Laboratories, Inc. | Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin |
| US4659563A (en) | 1986-01-27 | 1987-04-21 | Miles Laboratories, Inc. | High titer anti-respiratory syncytial virus intravenous immune globulin |
| US5271927A (en) | 1986-02-13 | 1993-12-21 | Celltech Limited | Antibody conjugates with macrocyclic ligands |
| US5468606A (en) | 1989-09-18 | 1995-11-21 | Biostar, Inc. | Devices for detection of an analyte based upon light interference |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US4800078A (en) * | 1987-05-28 | 1989-01-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb |
| US4880078A (en) * | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| GB8719041D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| US4916893A (en) * | 1987-09-02 | 1990-04-17 | Sundstrand Corporation | Multipurpose auxiliary power unit |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5223254A (en) | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
| EP0396563B1 (en) | 1987-12-23 | 1993-02-10 | The Upjohn Company | Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| US5183657A (en) | 1988-03-11 | 1993-02-02 | Celltech Limited | Antibodies for use in antilymphocyte antibody therapy |
| JPH01268646A (ja) | 1988-04-20 | 1989-10-26 | Meiji Milk Prod Co Ltd | 抗腫瘍剤 |
| US5137804A (en) | 1988-05-10 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Assay device and immunoassay |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5354554A (en) | 1989-02-10 | 1994-10-11 | Celltech Limited | Crosslinked antibodies and processes for their preparation |
| US6093872A (en) | 1989-05-05 | 2000-07-25 | Systemix, Inc. | Extended human hematopoiesis in a heterologous host |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5332567A (en) | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
| US5518725A (en) | 1989-09-25 | 1996-05-21 | University Of Utah Research Foundation | Vaccine compositions and method for induction of mucosal immune response via systemic vaccination |
| JP2571874B2 (ja) * | 1989-11-06 | 1997-01-16 | アルカーメス コントロールド セラピューティクス，インコーポレイテッド | タンパク質マイクロスフェア組成物 |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5279935A (en) | 1990-03-01 | 1994-01-18 | Becton, Dickinson And Company | Method of immunossay including deactivation of endogenous alkaline phosphatase |
| DK0481058T3 (da) | 1990-05-03 | 1996-12-02 | Systemix Inc | Humant, lymfatisk væv i en immunokompromitteret vært |
| US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
| CA2108259C (en) | 1991-04-22 | 2003-12-09 | George R. Siber | Process of screening plasma samples for effective antibody titers against respiratory viruses |
| CA2109528A1 (en) * | 1991-05-01 | 1992-11-02 | Gregory A. Prince | A method for treating infectious respiratory diseases |
| CA2044940A1 (en) | 1991-06-10 | 1992-12-11 | Inder M. Verma | Transdominant negative proto-oncogene |
| US5240694A (en) | 1991-09-23 | 1993-08-31 | University Of Virginia | Combined antiviral and antimediator treatment of common colds |
| US5418136A (en) | 1991-10-01 | 1995-05-23 | Biostar, Inc. | Devices for detection of an analyte based upon light interference |
| EP0614530B1 (en) * | 1991-11-15 | 1998-03-04 | Cornell Research Foundation, Inc. | Indirect immunoassay for dioxinlike compounds |
| US20020102257A1 (en) * | 1998-09-21 | 2002-08-01 | Leslie Sid Johnson | Human-murine chimeric antibodies against respiratory syncytial virus |
| US5667988A (en) * | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| ATE231002T1 (de) | 1992-09-16 | 2003-02-15 | Scripps Research Inst | Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus |
| US6685942B1 (en) * | 1993-12-10 | 2004-02-03 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
| EP0680337A4 (en) | 1993-01-12 | 1997-07-30 | Anthony George Gristina | METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY. |
| US5934272A (en) * | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US5424189A (en) | 1993-03-05 | 1995-06-13 | Kansas State University Research Foundation | Bovine respiratory syncytial virus detection and primers |
| AU689489B2 (en) * | 1993-07-30 | 1998-04-02 | Oravax, Inc | Monoclonal IgA antibody against respiratory syncytial virus |
| US5506209A (en) | 1994-05-26 | 1996-04-09 | Abbott Laboratories | Product for inhibition of infection of mammalian cells by respiratory syncytial virus |
| US5538952A (en) | 1994-05-26 | 1996-07-23 | Abbott Laboratories | Inhibition of infection of mammalian cells by respiratory syncytial virus |
| US5538733A (en) | 1994-07-07 | 1996-07-23 | Willmar Poultry Company, Inc. | Method of priming an immune response in a one-day old animal |
| US5792456A (en) * | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6019968A (en) * | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| WO1997007788A2 (en) * | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| DK0853487T3 (da) * | 1995-09-18 | 2000-10-23 | Us Health | Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus |
| ATE508733T1 (de) * | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| FR2758331B1 (fr) | 1997-01-14 | 1999-03-05 | Univ Bourgogne | Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux |
| US6117980A (en) * | 1997-02-21 | 2000-09-12 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US5989463A (en) * | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6572856B1 (en) * | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ATE474854T1 (de) | 2000-01-27 | 2010-08-15 | Medimmune Llc | Rsv neutralisierende antikörper mit sehr hohen affinität |
| US7229619B1 (en) * | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US20010034062A1 (en) * | 2000-02-09 | 2001-10-25 | Scott Koenig | Antibody gene therapy with adeno-associated viral vectors |
| EP2341075A1 (en) | 2000-03-01 | 2011-07-06 | MedImmune, LLC | Antibodies binding to the f protein of a respiratory syncytial virus (rsv) |
| AU2001241918A1 (en) * | 2000-03-02 | 2001-09-12 | Med Immune, Inc. | Methods of enhancing activity of vaccines and vaccine compositions |
| IL151348A0 (en) | 2000-04-13 | 2003-04-10 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
| ES2338098T3 (es) * | 2000-05-03 | 2010-05-04 | Medimmune, Llc | Terapia de combinacion de enfermedades respiratorias usando anticuerpos y agentes antiinflamatorios. |
| ATE300713T1 (de) | 2000-05-03 | 2005-08-15 | Ipv Inheidener Produktions Und | Thermobehälter |
| US20020004046A1 (en) * | 2000-05-03 | 2002-01-10 | Johnson Leslie S. | Combination therapy of respiratory diseases using antibodies |
| AU2001263443A1 (en) * | 2000-05-25 | 2001-12-03 | Med Immune, Inc. | F-protein epitope-based vaccine for respiratory syncytial virus infection |
| JP5490972B2 (ja) | 2000-08-04 | 2014-05-14 | 中外製薬株式会社 | タンパク質注射製剤 |
| US6565888B1 (en) * | 2000-08-23 | 2003-05-20 | Alkermes Controlled Therapeutics, Inc. | Methods and compositions for the targeted delivery of biologically active agents |
| US6855493B2 (en) * | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US7179900B2 (en) * | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| EP2412384A1 (en) | 2000-11-28 | 2012-02-01 | MedImmune, LLC | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US6818216B2 (en) * | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
| ES2727425T3 (es) | 2000-12-12 | 2019-10-16 | Medimmune Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| WO2006034292A2 (en) | 2004-09-21 | 2006-03-30 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| EP1812068A4 (en) * | 2004-10-29 | 2010-06-09 | Medimmune Inc | METHODS FOR PREVENTING AND TREATING RSV INFECTIONS AND ASSOCIATED DISEASES |
-
2001
- 2001-03-01 EP EP10010678A patent/EP2341075A1/en not_active Withdrawn
- 2001-03-01 EP EP01914657A patent/EP1259547B1/en not_active Expired - Lifetime
- 2001-03-01 US US09/796,848 patent/US7700735B2/en not_active Expired - Fee Related
- 2001-03-01 DK DK01914657.0T patent/DK1259547T3/da active
- 2001-03-01 AU AU4002001A patent/AU4002001A/xx active Pending
- 2001-03-01 CA CA002401652A patent/CA2401652A1/en not_active Abandoned
- 2001-03-01 PT PT01914657T patent/PT1259547E/pt unknown
- 2001-03-01 AU AU2001240020A patent/AU2001240020B9/en not_active Ceased
- 2001-03-01 EP EP10010677A patent/EP2341074A1/en not_active Withdrawn
- 2001-03-01 ES ES01914657T patent/ES2390761T3/es not_active Expired - Lifetime
- 2001-03-01 JP JP2001564244A patent/JP2003525061A/ja active Pending
- 2001-03-01 WO PCT/US2001/006815 patent/WO2001064751A2/en active Application Filing
-
2007
- 2007-05-08 AU AU2007202040A patent/AU2007202040B2/en not_active Ceased
-
2010
- 2010-02-09 JP JP2010026290A patent/JP2010162025A/ja active Pending
- 2010-02-17 US US12/707,527 patent/US8153133B2/en not_active Expired - Fee Related
- 2010-09-03 AU AU2010219289A patent/AU2010219289B2/en not_active Ceased
-
2012
- 2012-10-05 CY CY20121100934T patent/CY1113298T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06506836A (ja) * | 1991-04-10 | 1994-08-04 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二重体受容体ライブラリー |
| JPH10504195A (ja) * | 1994-08-15 | 1998-04-28 | メディミューン，インコーポレイテッド | 呼吸シンシチアルウイルスを防ぐヒト−マウスキメラ抗体 |
| JP2001511149A (ja) * | 1997-01-30 | 2001-08-07 | イクシーズ，インコーポレイテッド | 抗αｖβ３組換えヒト化抗体、これをコードする核酸、および使用の方法 |
Non-Patent Citations (7)
| Title |
|---|
| JPN6010071465, Ｊ Ｍｏｌ Ｂｉｏｌ， ｖｏｌ．３５０， ｐ．１２６−１４４ （２００５） * |
| JPN6010071466, Ｊ Ｍｏｌ Ｂｉｏｌ， ｖｏｌ．３６８， ｐ．６５２−６６５ （２００７） * |
| JPN6010071467, Ｊ Ｉｎｆｅｃｔ Ｄｉｓ， ｖｏｌ．１７６， ｐ．１２１５−１２２４ （１９９７） * |
| JPN6010071468, Ｐｒｏｃ Ｎａｔｌ Ａｃａｄ Ｓｃｉ ＵＳＡ， ｖｏｌ．９５， ｐ．６０３７−６０４２ （１９９８） * |
| JPN6010071469, Ｅｕｒ Ｊ Ｉｍｍｕｎｏｌ， ｖｏｌ．２７， ｐ．１２２１−１２２８ （１９９７） * |
| JPN6010071470, Ｊ Ｍｏｌ Ｂｉｏｌ， ｖｏｌ．２９４， ｐ．１５１−１６２ （１９９９） * |
| JPN6010071471, Ｊ Ｍｏｌ Ｂｉｏｌ， ｖｏｌ．２５４， ｐ．３９２−４０３ * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20020098189A1 (en) | 2002-07-25 |
| US7700735B2 (en) | 2010-04-20 |
| EP1259547B1 (en) | 2012-07-11 |
| EP1259547A2 (en) | 2002-11-27 |
| PT1259547E (pt) | 2012-10-15 |
| AU2010219289A1 (en) | 2010-09-30 |
| ES2390761T3 (es) | 2012-11-16 |
| JP2010162025A (ja) | 2010-07-29 |
| AU4002001A (en) | 2001-09-12 |
| AU2010219289B2 (en) | 2012-05-10 |
| DK1259547T3 (da) | 2012-10-15 |
| AU2001240020B9 (en) | 2008-12-04 |
| US8153133B2 (en) | 2012-04-10 |
| AU2007202040A1 (en) | 2007-05-24 |
| EP2341074A1 (en) | 2011-07-06 |
| AU2007202040B2 (en) | 2010-06-10 |
| WO2001064751A2 (en) | 2001-09-07 |
| AU2001240020B2 (en) | 2007-02-08 |
| CY1113298T1 (el) | 2016-04-13 |
| US20100239574A1 (en) | 2010-09-23 |
| CA2401652A1 (en) | 2001-09-07 |
| EP2341075A1 (en) | 2011-07-06 |
| WO2001064751A3 (en) | 2001-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003525061A (ja) | 高効力組換え抗体およびその産生法 | |
| AU2010201090B2 (en) | Ultra high affinity neutralizing antibodies | |
| AU2001240020A1 (en) | High potency recombinant antibodies and method for producing them | |
| WO2014028748A1 (en) | Interleukin 2 antibodies and antibody complexes | |
| BR112019012929A2 (pt) | anticorpos anti-il-5 | |
| JP2007525145A (ja) | 復活技術によって生成された炭疽菌毒素に対する中和ヒト抗体 | |
| WO2009068335A1 (en) | Human monoclonal nicotine specific antibodies | |
| AU2012211451A1 (en) | High potency recombinant antibodies and method for producing them | |
| AU2006203015B2 (en) | Ultra high affinity neutralizing antibodies | |
| AU2012213962A1 (en) | Ultra high affinity neutralizing antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080226 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20080226 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080409 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080417 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100209 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100312 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101214 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110310 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110317 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110404 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110411 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110609 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110705 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110912 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110920 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111227 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120515 |